Ieq Capital LLC Invests $244,000 in Insmed, Inc. $INSM

Key Points

• Ieq Capital LLC made a new investment in Insmed, Inc., purchasing 3,202 shares valued at approximately $244,000 in the first quarter.
• Analysts are bullish on Insmed, with 16 rating it as a "Buy" and target price estimates ranging from $100.00 to $145.00 per share.
• Despite missing EPS estimates in its latest quarterly results, Insmed reported revenue growth of 18.9% year-over-year, reaching $107.42 million.

Ieq Capital LLC acquired a new position in Insmed, Inc. (NASDAQ:INSM - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,202 shares of the biopharmaceutical company's stock, valued at approximately $244,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. M&T Bank Corp raised its stake in shares of Insmed by 4.7% in the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock worth $252,000 after purchasing an additional 147 shares during the last quarter. Snowden Capital Advisors LLC increased its position in shares of Insmed by 2.5% during the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock valued at $456,000 after acquiring an additional 158 shares during the last quarter. Cullen Frost Bankers Inc. increased its position in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 221 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of Insmed by 6.5% during the first quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company's stock valued at $287,000 after acquiring an additional 228 shares during the last quarter. Finally, Parkman Healthcare Partners LLC increased its position in shares of Insmed by 0.7% during the fourth quarter. Parkman Healthcare Partners LLC now owns 35,668 shares of the biopharmaceutical company's stock valued at $2,463,000 after acquiring an additional 235 shares during the last quarter.

Insider Transactions at Insmed

In other news, insider Michael Alexander Smith sold 24,272 shares of the firm's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $143.89, for a total value of $3,492,498.08. Following the completion of the transaction, the insider directly owned 54,902 shares of the company's stock, valued at $7,899,848.78. This trade represents a 30.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO William Lewis sold 129,805 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $100.39, for a total value of $13,031,123.95. Following the completion of the transaction, the chief executive officer directly owned 233,924 shares of the company's stock, valued at $23,483,630.36. The trade was a 35.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 378,382 shares of company stock valued at $40,169,038. 3.00% of the stock is currently owned by company insiders.

Insmed Stock Performance

NASDAQ:INSM traded up $0.14 during trading hours on Friday, reaching $145.93. The stock had a trading volume of 1,926,423 shares, compared to its average volume of 2,206,758. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The stock has a 50 day simple moving average of $119.40 and a 200 day simple moving average of $91.91. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $149.08. The stock has a market cap of $30.85 billion, a P/E ratio of -25.56 and a beta of 0.97.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $107.42 million during the quarter, compared to analysts' expectations of $104.06 million. During the same period in the prior year, the business earned ($1.94) earnings per share. The business's quarterly revenue was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. On average, research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Analysts Set New Price Targets

INSM has been the subject of a number of research analyst reports. Citigroup raised Insmed to a "buy" rating in a research report on Tuesday, June 10th. Morgan Stanley increased their price target on Insmed from $126.00 to $144.00 and gave the company an "equal weight" rating in a research report on Thursday, August 21st. JPMorgan Chase & Co. increased their price target on Insmed from $111.00 to $135.00 and gave the company an "overweight" rating in a research report on Wednesday, August 20th. Mizuho increased their price target on Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a research report on Wednesday, August 13th. Finally, Stifel Nicolaus increased their price target on Insmed from $121.00 to $145.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Sixteen investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $139.86.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.